Samuel S. Dychter

2.1k total citations
25 papers, 1.2k citations indexed

About

Samuel S. Dychter is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Samuel S. Dychter has authored 25 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Samuel S. Dychter's work include Proteoglycans and glycosaminoglycans research (6 papers), Glycosylation and Glycoproteins Research (4 papers) and Fibroblast Growth Factor Research (3 papers). Samuel S. Dychter is often cited by papers focused on Proteoglycans and glycosaminoglycans research (6 papers), Glycosylation and Glycoproteins Research (4 papers) and Fibroblast Growth Factor Research (3 papers). Samuel S. Dychter collaborates with scholars based in United States, United Kingdom and Japan. Samuel S. Dychter's co-authors include David Gold, Deborah Stier Carson, Michael Haller, Jayesh Desai, Jeffrey A. Morgan, Ming Hui Chen, George D. Demetri, P. Reed Larsen, Ellen Marqusee and Erik K. Alexander and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Samuel S. Dychter

24 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Samuel S. Dychter United States	14	544	268	256	180	142	25	1.2k
Kathryn Field Australia	21	539 1.0×	324 1.2×	173 0.7×	145 0.8×	41 0.3×	75	1.3k
Jason Tay Canada	20	341 0.6×	164 0.6×	394 1.5×	154 0.9×	104 0.7×	108	1.6k
Michele De Tursi Italy	18	576 1.1×	310 1.2×	239 0.9×	64 0.4×	117 0.8×	60	1.3k
Özlem Er Türkiye	15	594 1.1×	312 1.2×	241 0.9×	61 0.3×	35 0.2×	80	1.5k
Yoon Ji Choi South Korea	18	456 0.8×	282 1.1×	251 1.0×	101 0.6×	60 0.4×	111	1.1k
Prasad Mathew United States	28	501 0.9×	371 1.4×	587 2.3×	272 1.5×	212 1.5×	90	3.0k
Maria Rosaria Valerio Italy	21	745 1.4×	310 1.2×	186 0.7×	44 0.2×	154 1.1×	94	1.4k
Bhupinder Mann United Kingdom	18	528 1.0×	337 1.3×	1.2k 4.6×	156 0.9×	178 1.3×	43	2.2k
Iuliana Shapira United States	20	787 1.4×	247 0.9×	244 1.0×	60 0.3×	176 1.2×	53	1.6k
Jennifer Scalici United States	19	321 0.6×	164 0.6×	354 1.4×	267 1.5×	64 0.5×	59	1.6k

Countries citing papers authored by Samuel S. Dychter

Since Specialization

Citations

This map shows the geographic impact of Samuel S. Dychter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel S. Dychter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel S. Dychter more than expected).

Fields of papers citing papers by Samuel S. Dychter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel S. Dychter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel S. Dychter. The network helps show where Samuel S. Dychter may publish in the future.

Co-authorship network of co-authors of Samuel S. Dychter

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel S. Dychter. A scholar is included among the top collaborators of Samuel S. Dychter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel S. Dychter. Samuel S. Dychter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yoshino, T., Harpreet Wasan, Eric Van Cutsem, et al.. (2024). 515MO Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI). Annals of Oncology. 35. S435–S436. 4 indexed citations

Thomas, Stephen J., John L. Perez, Stephen Lockhart, et al.. (2021). 1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine. Annals of Oncology. 32. S1129–S1129. 9 indexed citations

Thomas, Stephen J., John L. Perez, Stephen Lockhart, et al.. (2021). Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. Vaccine. 40(10). 1483–1492. 38 indexed citations

Beachler, Daniel C., François-Xavier Lamy, Leo Russo, et al.. (2020). A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer. Journal of Ovarian Research. 13(1). 101–101. 12 indexed citations

Printz, Marie A., Samuel S. Dychter, Barry J. Sugarman, et al.. (2020). A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers. Current Therapeutic Research. 93. 100604–100604. 17 indexed citations

Pujade-Lauraine, Éric, Keiichi Fujiwara, Samuel S. Dychter, Geeta Devgan, & Bradley J. Monk. (2018). Avelumab (Anti-PD-L1) in Platinum-Resistant/Refractory Ovarian Cancer: JAVELIN Ovarian 200 Phase III Study Design. Future Oncology. 14(21). 2103–2113. 58 indexed citations

Infante, Jeffrey R., Ronald L. Korn, Lee S. Rosen, et al.. (2017). Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. British Journal of Cancer. 118(2). 153–161. 64 indexed citations

Hingorani, Sunil R., William Proctor Harris, J. Thaddeus Beck, et al.. (2016). Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clinical Cancer Research. 22(12). 2848–2854. 262 indexed citations

Dychter, Samuel S., et al.. (2016). Economic Burden of Acute Graft-Versus-Host Disease (GvHD) Following Allogeneic Hematopoietic Cell Transplant (HCT) for Hematologic Malignancies. Blood. 128(22). 1187–1187. 11 indexed citations

10.

Hendifar, Andrew, Sunil R. Hingorani, William Proctor Harris, et al.. (2015). LBA-02 High Response Rate and PFS with PEGPH20 added to Nab-Paclitaxel/Gemcitabine in Stage IV Previously Untreated Pancreatic Cancer Patients with High-HA Tumors: Interim Results of a Randomized Phase 2 Study. Annals of Oncology. 26. iv117–iv117. 2 indexed citations

11.

Rosengren, Sanna, Samuel S. Dychter, Marie A. Printz, et al.. (2015). Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration. The AAPS Journal. 17(5). 1144–1156. 44 indexed citations

12.

Dychter, Samuel S., et al.. (2014). Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers. Clinical Therapeutics. 36(2). 211–224. 16 indexed citations

13.

Schranz, Jennifer, Robyn J. Levy, William R. Lumry, et al.. (2012). Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Subcutaneous (SC) Cinryze® (C1 inhibitor (C1 INH) with Recombinant Human Hyaluronidase (rHuPH20) in Subjects with Hereditary Angioedema (HAE). Journal of Allergy and Clinical Immunology. 129(2). AB369–AB369. 4 indexed citations

14.

Dychter, Samuel S., David Gold, Deborah Stier Carson, & Michael Haller. (2012). Intravenous Therapy. Journal of Infusion Nursing. 35(2). 84–91. 162 indexed citations

15.

Dychter, Samuel S., David Gold, & Michael F. Haller. (2012). Subcutaneous Drug Delivery. Journal of Infusion Nursing. 35(3). 154–160. 56 indexed citations

16.

Maneval, Daniel C., Ramesh K. Ramanathan, Jeffrey R. Infante, et al.. (2012). Abstract 2672: Phase 1 pharmacokinetics (PK) & pharmacodynamics (PD) of PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors. Cancer Research. 72(8_Supplement). 2672–2672. 1 indexed citations

17.

Dychter, Samuel S., Ramesh K. Ramanathan, Jon Infante, et al.. (2011). PP 60 Targeting hyaluronan in tumor stroma. Interim translational and biomarker evaluations of pegylated hyaluronidase (PEGPH20) in animal models and patients with advanced solid tumors. European Journal of Cancer. 47. S30–S31. 2 indexed citations

18.

Dychter, Samuel S., et al.. (2009). Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: A phase IV, double-blind, randomized pilot study in healthy volunteers. Current Therapeutic Research. 70(6). 421–438. 13 indexed citations

19.

Desai, Jayesh, Ellen Marqusee, Suzanne George, et al.. (2006). Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors. Annals of Internal Medicine. 145(9). 660–664. 284 indexed citations

20.

Adamson, Robert, Samuel S. Dychter, Walter P. Dembitsky, et al.. (1998). Long-Term Outcome With the Use of OKT3 Induction Therapy in Heart Transplant Patients: A Single-Center Experience. Transplantation Proceedings. 30(4). 1107–1109. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact